- Home
- ARMP vs CTMX Comparison
ARMP vs CTMX Comparison
Compare ARMP & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- CTMX
- Stock Information
- Founded
- ARMP N/A
- CTMX 2008
- Country
- ARMP United States
- CTMX United States
- Employees
- ARMP N/A
- CTMX N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- CTMX Health Care
- Exchange
- ARMP Nasdaq
- CTMX Nasdaq
- Market Cap
- ARMP 80.0M
- CTMX 89.1M
- IPO Year
- ARMP N/A
- CTMX 2015
- Fundamental
- Price
- ARMP $2.72
- CTMX $1.02
- Analyst Decision
- ARMP Strong Buy
- CTMX Buy
- Analyst Count
- ARMP 1
- CTMX 6
- Target Price
- ARMP $7.00
- CTMX $5.77
- AVG Volume (30 Days)
- ARMP 8.3K
- CTMX 1.1M
- Earning Date
- ARMP 11-13-2024
- CTMX 11-07-2024
- Dividend Yield
- ARMP N/A
- CTMX N/A
- EPS Growth
- ARMP N/A
- CTMX N/A
- EPS
- ARMP N/A
- CTMX 0.16
- Revenue
- ARMP $3,719,000.00
- CTMX $126,617,000.00
- Revenue This Year
- ARMP N/A
- CTMX $11.79
- Revenue Next Year
- ARMP $83.33
- CTMX N/A
- P/E Ratio
- ARMP N/A
- CTMX $6.31
- Revenue Growth
- ARMP N/A
- CTMX 33.66
- 52 Week Low
- ARMP $1.93
- CTMX $0.98
- 52 Week High
- ARMP $4.48
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- ARMP 67.03
- CTMX 42.02
- Support Level
- ARMP $2.21
- CTMX $0.98
- Resistance Level
- ARMP $2.96
- CTMX $1.16
- Average True Range (ATR)
- ARMP 0.15
- CTMX 0.06
- MACD
- ARMP 0.05
- CTMX 0.01
- Stochastic Oscillator
- ARMP 68.42
- CTMX 17.58
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.